Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Cutaneous diffuse large B-cell lymphomas (DLBCLs) are aggressive hematologic malignancies with poor prognoses.
• Understanding the genetic landscape of DLBCLs is crucial for developing targeted therapies.

Purpose of the Study:

• To elucidate the genetic underpinnings of cutaneous DLBCLs, specifically DLBCLs of the leg type (DLBCL-LT) and DLBCLs-not otherwise specified (DLBCL-NOS).
• To identify potential therapeutic targets and treatment strategies based on genetic alterations.

Main Methods:

• Whole-exome sequencing of 37 cutaneous DLBCL samples (31 DLBCL-LT, 6 DLBCL-NOS).
• Analysis of mutations in key signaling pathways including NF-κB, immune evasion, and PD-L1/PD-L2.
• Comparison of genetic profiles between DLBCL-LT and DLBCL-NOS, and with other lymphoma subtypes.

Main Results:

• MYD88 mutations activating the NF-κB pathway were found in 77% of DLBCL-LT.
• Alternative NF-κB pathway activation or other cancer pathway mutations (BRAF, PIK3R1, STAT3) were identified in MYD88-wild-type DLBCL-LT.
• Mutations affecting antigen processing (B2M, CIITA, HLA) and T-cell co-stimulation (CD58) were common, suggesting immune evasion mechanisms.
• DLBCL-LT showed genetic similarities to primary central nervous system lymphomas and primary testicular lymphomas, including PDL1/PDL2 translocations in 40% of cases.
• DLBCL-LT had limited genetic overlap with the heterogeneous DLBCL-NOS subtype.

Conclusions:

• Cutaneous DLBCLs, particularly DLBCL-LT, are driven by distinct genetic alterations, including NF-κB pathway activation and immune evasion mechanisms.
• The genetic profile of DLBCL-LT suggests potential therapeutic strategies targeting BRAF, PI3K, or immune checkpoints (e.g., PD-1/PD-L1 inhibitors).
• DLBCL-LT shares genomic features with primary central nervous system and testicular lymphomas, supporting the investigation of similar treatment paradigms.